Ribociclib (KisqaliTM) for HR-positive/HER2-negative advanced or metastatic breast cancer; brigatinib (AlunbrigTM) for ALK-positive non-small-cell lung cancer; abemaciclib (VerzenioTM) for breast cancer; copanlisib (AliqopaTM) for follicular lymphoma; telotristat ethyl (XermeloTM) for carcinoid syndrome diarrhea; and letermovir (PrevymisTM) for the prevention of infection after bone marrow transplant. This evidence concerns the gene ERBB2 and breast carcinoma.